BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top most undervalued low volatility stocks to buy now. On August 25, BMO Capital analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00.

The analyst supported the rating with the present performance and future expectations for Bristol-Myers Squibb Company’s (NYSE:BMY) product, Cobenfy.

Seigerman stated that the drug exhibited solid prescription growth, but the rate did not point to a considerable market breakthrough. The analyst expects the numbers to fall short of the consensus revenue expectations for fiscal Q3 2025 despite a rise in the weekly and monthly prescriptions.

Seigerman added that the revised assumptions regarding inventory levels and gross-to-net discounts add increased uncertainty to revenue forecasts, supporting the Hold rating.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.